Some stock data isn't available right now.
Savara Inc. (SVRA)
Underlying price
$4.29-17.58% last session
Â
Stock stats
- $939M
- $5.21
- $4.19
- $3.50 – $5.42
- $4.00 – $7.00
- 16.5M
- 2.81M
- -
- 0.408
- -$0.6
- -
- 0.388
Analysts & earnings
Analyst ratings
Buy, 4.33 on a scale from 1, strong sell, to 5, strong buy
- 3 Strong buy
- 6 Buy
- 0 Hold
- 0 Sell
- 0 Strong sell
$10.83+152.21%
- Today
- $4.29
- Target
- $10.83
Earnings per share
Beat estimates 1 of last 4
- Estimate
- Actual
- Mar '26: actual -$0.13, estimate -$0.12
- May '26: actual -$0.1472, estimate -$0.1183
- Aug '26: actual -$0.16, estimate -$0.14
- Nov '26: actual -$0.17, estimate -$0.18
About Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
- Ticker
- SVRA
- Asset class
- Equity
- Tokenized by
- 0 issuers
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Employees
- 70
- Website
- savarapharma.com